Journal
CANCER LETTERS
Volume 247, Issue 1, Pages 130-136Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2006.03.029
Keywords
CA125; mesothelin; high-throughput screening; cell adhesion model system; ovarian cancer
Categories
Funding
- NCI NIH HHS [P50 CA83636, P50 CA083636, P50 CA083636-06] Funding Source: Medline
- NIGMS NIH HHS [R37 GM017709, R01 GM017709-31, R01 GM017709, GM 17709] Funding Source: Medline
Ask authors/readers for more resources
Preventing peritoneal implantation of ovarian carcinoma cells could prolong patient remission and survival. CA125 is expressed on most ovarian cancer cells and was reported to be a ligand of mesothelin, a peritoneal protein. We developed a cell adhesion assay with CA125-expresser ovarian cancer cells and human mesothelin-transfected cells and we confirmed that CA125 and mesothelin mediate cell attachment. We also showed that this assay supplies a high-throughput screening system for reagents able to block CA125/mesothelin-dependent cell attachment with a sensitive quantitative readout. We finally demonstrated that a mesothelin chimeric protein and anti-CA125 antibodies block CA125/mesothelin-dependent cell attachment. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available